NCT00365222View on ClinicalTrials.gov

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

GlioblastomaGliosarcoma

Interventions

DRUG

Temozolomide

temozolomide 75 mg/m2 /d

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER